OBJECTIVES: To evaluate the impact of selective fluconazole prophylaxis on incidence of invasive fungal infection and emergence of fluconazole resistance in neonatal intensive care. DESIGN: Retrospective study of very low birthweight (VLBW) babies (<1500 g birth weight) admitted to a neonatal intensive care unit (NICU) in the period 1 year before and after the implementation of an antifungal prophylaxis guideline. PATIENTS: VLBW babies with an additional risk factor: colonisation of Candida species from surface sites with a central venous catheter; third generation cephalosporin treatment; or total duration of antibiotic treatment >10 days. Fluconazole protocol: Fluconazole 6 mg/kg for 3 weeks. Dose interval is every 72 h during the first 2 weeks of life. Thereafter, dose interval is reduced to every 48 h until 3 weeks old when daily fluconazole is given. Fluconazole is administered orally when enteral feeding achieved. RESULTS: 121 and 107 VLBW babies were admitted to the NICU in the year before and after the guideline was implemented, respectively. Data were available in 110 and 102 charts. 33/110 and 31/102 babies were eligible for fluconazole prophylaxis in the period before and after guideline implementation. 6/33 babies eligible for prophylaxis developed culture proven Candida sepsis before compared with no (0/31) babies after the guideline was implemented (p = 0.03). One baby (1/31) did develop probable Candida sepsis in the post guideline implementation period. During both study periods all Candida isolates remained fully susceptible to fluconazole. CONCLUSIONS: Selective antifungal prophylaxis has reduced invasive fungal sepsis in one NICU without evidence of fluconazole resistance emerging.
OBJECTIVES: To evaluate the impact of selective fluconazole prophylaxis on incidence of invasive fungal infection and emergence of fluconazole resistance in neonatal intensive care. DESIGN: Retrospective study of very low birthweight (VLBW) babies (<1500 g birth weight) admitted to a neonatal intensive care unit (NICU) in the period 1 year before and after the implementation of an antifungal prophylaxis guideline. PATIENTS: VLBW babies with an additional risk factor: colonisation of Candida species from surface sites with a central venous catheter; third generation cephalosporin treatment; or total duration of antibiotic treatment >10 days. Fluconazole protocol: Fluconazole 6 mg/kg for 3 weeks. Dose interval is every 72 h during the first 2 weeks of life. Thereafter, dose interval is reduced to every 48 h until 3 weeks old when daily fluconazole is given. Fluconazole is administered orally when enteral feeding achieved. RESULTS: 121 and 107 VLBW babies were admitted to the NICU in the year before and after the guideline was implemented, respectively. Data were available in 110 and 102 charts. 33/110 and 31/102 babies were eligible for fluconazole prophylaxis in the period before and after guideline implementation. 6/33 babies eligible for prophylaxis developed culture proven Candida sepsis before compared with no (0/31) babies after the guideline was implemented (p = 0.03). One baby (1/31) did develop probable Candida sepsis in the post guideline implementation period. During both study periods all Candida isolates remained fully susceptible to fluconazole. CONCLUSIONS: Selective antifungal prophylaxis has reduced invasive fungal sepsis in one NICU without evidence of fluconazole resistance emerging.
Authors: M H Nguyen; J E Peacock; A J Morris; D C Tanner; M L Nguyen; D R Snydman; M M Wagener; M G Rinaldi; V L Yu Journal: Am J Med Date: 1996-06 Impact factor: 4.965
Authors: B J Stoll; T Gordon; S B Korones; S Shankaran; J E Tyson; C R Bauer; A A Fanaroff; J A Lemons; E F Donovan; W Oh; D K Stevenson; R A Ehrenkranz; L A Papile; J Verter; L L Wright Journal: J Pediatr Date: 1996-07 Impact factor: 4.406
Authors: M A Pfaller; S R Lockhart; C Pujol; J A Swails-Wenger; S A Messer; M B Edmond; R N Jones; R P Wenzel; D R Soll Journal: J Clin Microbiol Date: 1998-06 Impact factor: 5.948
Authors: Daniel K Benjamin; Elizabeth R DeLong; William J Steinbach; Charles M Cotton; Thomas J Walsh; Reese H Clark Journal: Pediatrics Date: 2003-09 Impact factor: 7.124
Authors: Kevin Watt; Paolo Manzoni; Michael Cohen-Wolkowiez; Stefano Rizzollo; Elena Boano; Evelyne Jacqz-Aigrain; Daniel K Benjamin Journal: Curr Drug Metab Date: 2013-02 Impact factor: 3.731
Authors: Jessica E Ericson; David A Kaufman; Stephen D Kicklighter; Jatinder Bhatia; Daniela Testoni; Jamie Gao; P Brian Smith; Kristi O Prather; Daniel K Benjamin Journal: Clin Infect Dis Date: 2016-06-13 Impact factor: 20.999